Thursday, November 9, 2017

Oyster Point Pharma Finds $22M For Dry Eye Treatment

San Francisco-based Oyster Point Pharmaceuticals, a startup developing therapies for treating "dry eye" and other ocular diseases, said this week that it has raised $22M in a funding round. The funding was led by Versant Ventures and New Enterprise Associates (NEA). The company said funds will go to fund its efforts through Phase II clinical trials. Oyster Point's President and CEO is Jeffrey Nau.